Comparison of efficacy and tolerability of amlodipine orotate versus amlodipine besylate in adult patients with mild to moderate hypertension: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, 8-week follow-up, noninferiority trial

Clinical Therapeutics

Volumn 28, Issue 4, 2006, Pages 537-551

  Hong, Soon Jun ^a   Ahn, Tae Noon ^b   Baek, Sang Hong ^c   Cho, Wook Hyun ^d   Jeon, Hyee Kyoung ^e   Kyun, Jun ^f   Yoon, Myeong Ho ^g   Lee, Kwan Jeh ^h   Lim, Do Sun ^a  

^a Korea University College of Medicine   (South Korea)

^b Gachon University College of Medicine   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Inje University College of Medicine   (South Korea)

^e Uijeongbu St Mary's Hospital   (South Korea)

^f Inha University Hospital   (South Korea)

^g Ajou University Medical Center   (South Korea)

^h Dongguk University   (South Korea)

Author keywords

amlodipine; antihypertensive therapy; calcium channel blocker; hypertension; orotate

Indexed keywords

AMLODIPINE BESYLATE; AMLODIPINE OROTATE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; ORODIPINE; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CIGARETTE SMOKING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; JOINT SWELLING; KOREA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; HYPERTENSION; KOREA; MALE; MIDDLE AGED;

EID: 33646869023     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.04.008     Document Type: Article

References (36)

1. Wolf-Maier K., Cooper R.S., Banegas J.R., et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289 (2003) 2363-2369
2. Volpe M., Junren Z., Maxwell T., et al., CDSP-944 Study Group. Comparison of the blood pressure-lowering effects and tolerability of losartan- and amlodipine-based regimens in patients with isolated systolic hypertension. Clin Ther 25 (2003) 1469-1489
3. [published correction appears in N Eng1J Med. 2002;346:544]. Hyman D.J., and Pavlik v.N. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 345 (2001) 479-486
4. Chobanian A.V., Bakris G.L., Black H.R., et al., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report [published correction appears in JAMA. 2003:290:197]. JAMA 289 (2003) 2560-2572
5. Oparil S., and Calhoun D.A. The calcium antagonists in the 1990s. An overview. Am J Hypertens 4 (1991) 3965-4055
6. Messerli F.H. Case-control study, meta-analysis, and bouillabaisse: Putting the calcium antagonist scare into context. Ann Intern Med 123 (1995) 888-889
7. Kes S., Caglar N., Canberk A., et al. Treatment of mild-tomoderate hypertension with calcium channel blockers: A multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine. CurrMed Res Opin 19 (2003) 226-237
8. Elliott H.L., Elawad M., Wilkinson R., and Singh S.P. Persistence of anti hypertensive efficacy after missed doses: Comparison of amlodipine and nifedipine gastrointestinal therapeutic system. J Hypertens 20 (2002) 333-338
9. Abernethy D.R., Gutkowska J., and Winterbottom L.M. Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: Pharmacodynamics in relation to disposition. Clin Pharmacol Ther 48 (1990) 76-86
10. discussion 1119-1120. Osterloh I. The safety of amlodipine. Am Heart J 118 (1989) 1114-1119
11. Park J.Y., Kim K.A., Lee G.S., et al. Randomized, open-label, two-period crossover comparison of the pharmacokinetic and pharmacodynamic properties of two amlodipine for mulations in healthy adult male Korean subjects. Clin Ther 26 (2004) 715-723
12. Kwak H.H., Kim J.O., Chung H.K., et al. Pharmacokinetics of oral amlodipine orotate in vagotomized dogs. Biopharm Drug Dispos 27 (2006) 141-145
13. In: Stahl P.H., and Wermuth C.G. (Eds). Handbook of Pharmaceutical Salts: Properties, Selection, and Use (2002), Wiley VCH, Weinheim, Germany
14. Chobanian A.V., Bakris G.L., Black H.R., et al., Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
15. Siegel J.P. Equivalence and non inferiority trials. Am Heart J 139 (2000) S166-S170
16. Oparil S., Barr E., Elkins M., et al. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydro chlorothiazide, in patients with essential hypertension. Clin Ther 18 (1996) 608-625
17. Zidek W., Spiecker C., Knaup G., et al. Comparison of the efficacy and safety of nifedipine coat-core versus amlodipine in the treatment of patients with mild-to-moderate essential hypertension. Hypertension Study Group. Clin Ther 17 (1995) 686-700
18. Wilson T.W., Lacourciere Y., and Barnes C.C. The anti hypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. Canadian Cozaar Hyzaar Amlodipine Trial Study Group. CMAJ 159 (1998) 469-476
19. Whitcomb C., Enzmann G., Pershadsingh H.A., et al. A comparison of nisoldipine ER and amlodipine for the treatment of mild to moderate hypertension. Int J Clin Pract 54 (2000) 509-513
20. Clark L.T. Improving compliance and increasing control of hypertension: Needs of special hypertensive popu lations. Am Heart J 121 (1991) 664-669
21. Shin E.K., Chung W.S., Seo H.S., et al. Efficacy and safety of amlodipine camsylate for treatment of essential hypertension. Korean Circulation J 35 (2005) 247-252
22. Poulter N.R., Wedel H., Dahlof B., et al., ASCOT Investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 366 (2005) 907-913
23. Julius S., Kjeldsen S.E., Weber M., et al., VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 363 (2004) 2022-2031
24. Lee H.Y., Kang H.J., Koo B.K., et al., Amostar Study Investigators. Clinic blood pressure responses to two amlodipine salt formulations, adipate and besylate, in adult Korean patients with mild to moderate hypertension: A multicenter, randomized, double-blind, parallel-group, 8-week comparison. Clin Ther 27 (2005) 728-739
25. Park S., Chung N., Kwon J., et al. Results of a multicenter, 8-week, parallel-group, randomized, double blind, double-dummy, phase III clinical trial to evaluate the efficacy and tolerability of amlodipine maleate versus amlodipine besylate in Korean patients with mild to moderate hypertension. Clin Ther 27 (2005) 441-450
26. Hall R., and Chong C. A double-blind, parallel-group study of amlodipine versus long-acting nitrate in the man agement of elderly patients with stable angina. Cardiology 96 (2001) 72-77
27. Pedrinelli R., Dell'Omo G., Nuti M., et al. Heterogeneous effect of calcium antagonists on leg oedema: A com parison of amlodipine versus lercanidipine in hypertensive patients. J Hypertens 21 (2003) 1969-1973
28. Pedrinelli R., Dell'Omo G., Melillo E., and Mariani M. Amlodipine, enalapril, and dependent leg edema in essen tial hypertension. Hypertension 35 (2000) 621-625
29. [published correction appears in Lancet. 2000; 356:514]. Brown M., Palmer C.R., Castaigne A., et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calciumchannel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356 (2000) 366-372
30. Messerli F.H. Vasodilatory edema: A common side effect of antihypertensive therapy. Am J Hypertens 14 (2001) 978-979
31. [published correction appears in Drugs. 1995; 50:896]. Haria M., and Wagstaff A.J. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 50 (1995) 560-586
32. Frick M.H., McGibney D., and Tyler H.M. A dose-response study of amlodipine in mild to moderate hypertension. J Intern Med. 225 (1989) 101-105
33. Fang J., and Alderman M.H. Serum uric acid and cardiovascular mortality in the NHANES I epidemiologic follow up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 283 (2000) 2404-2410
34. Johnson R.J., Kang D..H., Feig D., et al. Is there a pathogenetic role for uric acid in hypertension and cardiovas cular and renal disease?. Hypertension 41 (2003) 1183-1190
35. Hoieggen A., Alderman M.H., Kjeldsen S.E., et al., LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidneylnt 65 (2004) 1041-1049
36. [published correction appears in Lancet 2003;361:1060]. Lewington S., Clarke R., Qizilbash N., et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002) 1903-1913